Integrative Genomics Identifies Gene Signature Associated with Melanoma Ulceration

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Rakosy, Zsuzsa ^a,b   Ecsedi, Szilvia ^a,b   Toth, Reka ^a   Vizkeleti, Laura ^a,b   Herandez Vargas, Hector ^d   Lazar, Viktoria ^a   Emri, Gabriella ^c   Szatmari, Istvan ^c   Herceg, Zdenko ^d   Adany, Roza ^a,b   Balazs, Margit ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CLAUDIN 1; COLLAGEN TYPE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EZRIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KALININ; KALLIKREIN 5; KRUPPEL LIKE FACTOR 4; OCCLUDIN; OSTEOPONTIN; PROTEIN P21; PROTEIN P53; WNT PROTEIN;

ADULT; ANOCTAMIN 1 GENE; APOPTOSIS; ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; ARTICLE; CANCER PROGNOSIS; CELL ADHESION; CELL CYCLE REGULATION; CELL INTERACTION; CHROMOSOME 10Q; CHROMOSOME 6Q; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER LOSS; COPY NUMBER VARIATION; CPG ISLAND; DISEASE CLASSIFICATION; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; ERYTHROPOIETIN PRODUCING HEPATOCYTE KINASE B3 GENE; ERYTHROPOIETIN PRODUCING HEPATOCYTE KINASE B6 GENE; EZRIN GENE; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC PARAMETERS; GENOME ANALYSIS; GENOMICS; HUMAN; HUMAN TISSUE; IL20RA GENE; INTEGRATIVE GENOMICS; INTRACELLULAR SIGNALING; KALLIKREIN 11 GENE; KALLIKREIN 5 GENE; KLF4 GENE; MALE; MELANOMA; MYB1 GENE; OSTEOPONTIN GENE; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCER; UPREGULATION; VALIDATION PROCESS;

ADULT; CPG ISLANDS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MALE; MELANOMA; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; ULCER; YOUNG ADULT;

EID: 84873881608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054958     Document Type: Article

References (63)

1. Forschner A, Eigentler TK, Pflugfelder A, Leiter U, Weide B, et al. (2010) Melanoma staging: facts and controversies. Clin Dermatol 28: 275-280.
2. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, et al. (2011) Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer 2: 538-543.
3. Ha L, Merlino G, Sviderskaya EV, (2008) Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle 7: 1944-1948.
4. Daryanani D, Plukker JT, Nap RE, Kuiper H, Hoekstra HJ, (2006) Adolescent melanoma: risk factors and long term survival. Eur J Surg Oncol 32: 218-223.
5. Gaudi S, Messina JL, (2011) Molecular bases of cutaneous and uveal melanomas. Patholog Res Int 2011: 159421.
6. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, et al. (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
7. Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, et al. (2007) Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Ann Surg Oncol 14: 1416-1423.
8. Berthier-Vergnes O, Kharbili ME, de la Fouchardiere A, Pointecouteau T, Verrando P, et al. (2011) Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion. Br J Cancer 104: 155-165.
9. Freedman JA, Tyler DS, Nevins JR, Augustine CK, (2011) Use of gene expression and pathway signatures to characterize the complexity of human melanoma. Am J Pathol 178: 2513-2522.
10. Valsesia A, Rimoldi D, Martinet D, Ibberson M, Benaglio P, et al. (2011) Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS One 6: e18369.
11. Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, et al. (2010) Integrative genome comparison of primary and metastatic melanomas. PLoS One 5: e10770.
12. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, et al. (2009) A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 4: e8461.
13. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, et al. (2010) Aberrant DNA methylation in malignant melanoma. Melanoma Res 20: 253-265.
14. Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, et al. (2011) DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res 24: 352-360.
15. Martins WK, Esteves GH, Almeida OM, Rezze GG, Landman G, et al. (2011) Gene network analyses point to the importance of human tissue kallikreins in melanoma progression. BMC Med Genomics 4: 76.
16. Dietel M, (2007) Predictive pathology of cytostatic drug resistance and new anti-cancer targets. Recent Results Cancer Res 176: 25-32.
17. Kunz M, (2008) Genomic signatures for individualized treatment of malignant tumors. Curr Drug Discov Technol 5: 9-14.
18. Koh SS, Opel ML, Wei JP, Yau K, Shah R, et al. (2009) Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue. Mod Pathol 22: 538-546.
19. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102: 6092-6097.
20. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, et al. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98: 472-482.
21. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, et al. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540.
22. Smith AP, Hoek K, Becker D, (2005) Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4: 1018-1029.
23. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, et al. (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13: 806-815.
24. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, et al. (2007) A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67: 3450-3460.
25. Timar J, Gyorffy B, Raso E, (2010) Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis 27: 371-387.
26. Jonsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, et al. (2007) Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 26: 4738-4748.
27. Goppner D, Leverkus M, (2011) Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? J Skin Cancer 2011: 521947.
28. Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, et al. (2010) Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 23: 763-770.
29. Rakosy Z, Vizkeleti L, Ecsedi S, Voko Z, Begany A, et al. (2007) EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 121: 1729-1737.
30. Berger MF, Garraway LA (2009) Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am 23: 397-414, vii.
31. Gao K, Lockwood WW, Li J, Lam W, Li G, (2008) Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells. Int J Oncol 32: 1343-1349.
32. Yeang CH, (2010) An integrated analysis of molecular aberrations in NCI-60 cell lines. BMC Bioinformatics 11: 495.
33. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, et al. (2011) Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 71: 2561-2571.
34. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648.
35. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
36. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, et al. (2010) Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 5: e9749.
37. Goeman JJ, (2010) L1 penalized estimation in the Cox proportional hazards model. Biom J 52: 70-84.
38. van de Wiel MA, Wieringen WN, (2007) CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Inform 3: 55-63.
39. Yuan Y, Curtis C, Caldas C, Markowetz F, (2012) A sparse regulatory network of copy-number driven gene expression reveals putative breast cancer oncogenes. IEEE/ACM Trans Comput Biol Bioinform 9: 947-954.
40. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
41. O'Connell MP, Weeraratna AT, (2009) Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res 22: 724-739.
42. Chudnovsky Y, Khavari PA, Adams AE, (2005) Melanoma genetics and the development of rational therapeutics. J Clin Invest 115: 813-824.
43. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, et al. (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565-573.
44. Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, et al. (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4: 50.
45. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, et al. (2010) Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 17: 2006-2014.
46. In 't Hout FE, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, et al. (2012) Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann Surg 255: 1165-1170.
47. Eggermont AM, Spatz A, Lazar V, Robert C, (2012) Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 24: 137-140.
48. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, et al. (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15: 6939-6946.
49. Buback F, Renkl AC, Schulz G, Weiss JM, (2009) Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 18: 750-759.
50. Mitra A, Conway C, Walker C, Cook M, Powell B, et al. (2010) Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer 103: 1229-1236.
51. Blokx WA, van Dijk MC, Ruiter DJ, (2010) Molecular cytogenetics of cutaneous melanocytic lesions- diagnostic, prognostic and therapeutic aspects. Histopathology 56: 121-132.
52. Gerami P, Beilfuss B, Haghighat Z, Fang Y, Jhanwar S, et al. (2011) Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi. J Cutan Pathol 38: 329-334.
53. Stark M, Hayward N, (2007) Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 67: 2632-2642.
54. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, et al. (2001) Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104: 9-19.
55. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, et al. (2010) Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 49: 733-745.
56. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, et al. (2009) Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 7: 1438-1445.
57. Ilmonen S, Vaheri A, Asko-Seljavaara S, Carpen O, (2005) Ezrin in primary cutaneous melanoma. Mod Pathol 18: 503-510.
58. Conway C, Beswick S, Elliott F, Chang YM, Randerson-Moor J, et al. (2010) Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer 49: 425-438.
59. Rakosy Z, Vizkeleti L, Ecsedi S, Begany A, Emri G, et al. (2008) Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 182: 116-121.
60. Howell PM Jr, Liu S, Ren S, Behlen C, Fodstad O, et al. (2009) Epigenetics in human melanoma. Cancer Control 16: 200-218.
61. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, et al. (2004) Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95: 962-968.
62. Christensen BC, Houseman EA, Poage GM, Godleski JJ, Bueno R, et al. (2010) Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res 70: 5686-5694.
63. Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, et al. (2010) Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted. PLoS One 5: e9651.